BU-NOT-SET

CONTACT US
For lyophilisation, excipients really do matter
  • Drug product
Eyes
Insight
The challenges of serialisation
  • Manufacturing
Eyes
Insight
The oncolytic efficacy and in vivo pharmacokinetics of [2-(4- Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol (Vacquinol-1) are governed by distinct stereochemical features
  • Drug substance
Eyes
Insight
Strategies to prepare for serialisation
  • Manufacturing
Eyes
Insight
A Versatile One-Pot Procedure for the Synthesis of 5-Aryl-6H- 1,3,4-thiadiazine-2-amines from Aromatic Ketones
  • Drug substance
Eyes
Insight
Insight
  • Manufacturing
Serialisation | the past, the present and the future
Insight
  • Industry trends
Mergers and acquisitions | meeting customer demand
Insight
  • Manufacturing
DSCSA deadline | our views
Insight
  • Manufacturing
Serialisation: an investment not an expense
Insight
  • Drug product
Solving the solubility setback
Insight
  • Industry trends
Pharmaceutical mega-trends: the rise of consolidation
Insight
  • Manufacturing
What the new Drug Supply Chain Security Act (DSCSA) deadline means for the industry
Insight
  • Drug substance
Automating excipient selection using high-throughput screening
Insight
  • Manufacturing
Serialisation: is the industry ready?